Results of SIGNAL‐AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of targeting reactive astrocytes with pepinemab, SEMA4D blocking antibody, in people with mild Alzheimer’s dementia
SIGNAL-AD 是一项随机、1b/2 期试验，旨在评估使用 SEMA4D 阻断抗体 pepinemab 靶向反应性星形胶质细胞治疗轻度阿尔茨海默病痴呆患者的安全性和有效性。
期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0165704
Janiszewska, Jolanta; Posadas, Inmaculada; Játiva, Pablo; Bugaj-Zarebska, Marta; Urbanczyk-Lipkowska, Zofia; Ceña, Valentín; Martins, Gabriel Colissi; Limberger, Christian; Hoffmeister, Gabriel Lermen; Schmaedek, Mariana Radaelli; de Souza, Ramon Bertoldi; de Oliveira, Roberta dos Santos; Bastiani, Marco Antônio De; Zimmer, Eduardo R; Siemers, Eric R; Evans, Elizabeth E; Fisher, Terrence L Jr; Boise, Megan; Foster, Amber; Leonard, John E; Mishra, Vikas; Mallow, Crystal L; Porsteinsson, Anton P; Turner, Raymond Scott; Bond, Wendy; Huffaker, John; Farlow, Martin R; Honig, Lawrence S; Sheldon, Elizabeth; Townley, Ryan A; Winner, Paul; Norton, Jeffrey; Holub, Richard; Patel, Paayal; Geldmacher, David S; Capote, Horatio; Thein, Stephen; Zauderer, Maurice
